Background {#Sec1}
==========

As with many procedures \[[@CR1], [@CR2]\], patients often cite a fear of needles as a major reason to decline Nexplanon® placement. Nexplanon® is a long-acting removable contraceptive device that is traditionally inserted in the upper arm under local anesthesia using a needle to inject a lidocaine solution \[[@CR3]\]. A jet injector device that injects lidocaine under high pressure without the use of needles has been studied in other medical settings, including dental \[[@CR1]\] and urologic \[[@CR2]\] procedures, as well as other procedures requiring local anesthetic \[[@CR4]\]. The objective of this study was to determine if the jet injection method of local anesthesia is effective for removal and insertion of the Nexplanon® device, whether the pain of the injection of lidocaine differed between the methods of delivery, and whether the presence or absence of needles in the anesthesia method affected patient anxiety level.

Methods {#Sec2}
=======

All adult women of childbearing age who were undergoing insertion or removal of a Nexplanon® device for contraception at a residency-based Family Medicine clinic were invited to be a part of the study. Any persons who declined to be a part of the study had the device inserted by established protocol with needle anesthesia and their data were not used. Expedited IRB approval was obtained prior to starting the study. Patients were randomized via random computerized assignment to one of two methods of anesthesia: The intervention group received 1% lidocaine delivered to the site of insertion or removal via Jet-injector device; the control group received 1% lidocaine using a needle injection. For our study, a spring-loaded jet injector was used. Gas/air powered jet injectors are also available. Per protocol for the respective anesthetic devices, 1--2 ml was used with needle-injected anesthesia, and 8 to 10 jets of lidocaine (each 0.1 ml) were used along the insertion or removal tract for jet injected anesthesia. No differentiation in anesthetic dose was made between insertion and removal as similar amounts of anesthetic are routinely used for both procedures. A patient survey (Table [1](#Tab1){ref-type="table"}) was administered by the investigator 5 to 10 min after the procedure was finished. The provider performing the procedure also answered questions (Table [1](#Tab1){ref-type="table"}) related to the perceived patient experience and ease of use of the respective delivery method. Table 1Patient and Provider QuestionnaireQuestions for patients PQ1. Before your procedure, were you worried that the procedure might be painful?  1-Not at all worried  2-Slightly worried  3-Moderately worried  4-Very worried  5-Extremely worried PQ2. When you saw the needle (or jet injector device), did you become anxious?  1-Not at all anxious at all  2-Slightly anxious  3-Moderately anxious  4-Very anxious  5-Extremely anxious PQ 3. Did you experience pain with the numbing injection?  1-No pain at all  2-Slight pain  3-Moderate pain  4-Very painful  5-Extremely painful PQ4. Did you experience pain when the Nexplanon was inserted or removed?  1-No pain at all  2-Slight pain  3-Moderate pain  4-Very painful  5-Extremely painfulQuestions for doctors DQ1. Was the anesthesia method easy to use?  1-Very difficult to use  2-Difficult to use  3-Fairly easy to use  4-Easy to use  5-Very easy to use DQ2. Did the patient experience discomfort with the lidocaine injection?  1-No discomfort at all  2-Slight discomfort  3-Moderate discomfort  4-Serious discomfort  5-Extreme discomfort DQ3. Did the method of anesthesia provide adequate anesthesia for the placement or removal of the Nexplanon®?  1-Very poor  2-Poor  3-Fair  4-Good  5-Excellent

Statistical methods {#Sec3}
===================

The distributions of survey questions were assessed for the statistical assumption of normality using skewness and kurtosis statistics (Table [2](#Tab2){ref-type="table"}). Levene's Test of Equality of Variances was used to check for the statistical assumption of homogeneity of variance. Between-subject statistics were used to compare the needle injection group versus the jet injector group on the survey questions. When statistical assumptions were met, parametric independent samples *t*-tests were used to compare the groups on the continuous survey item responses. When either or both statistical assumptions were violated, non-parametric Mann-Whitney *U* tests were used for between-subject comparisons. Statistical significance was assumed a Bonferroi-adjusted alpha value of 0.007 to account for increased experiment-wise error rates when testing multiple hypotheses concurrently. All analyses were conducted using SPSS Version 25 (Armonk, NY: IBM Corp.). The study was adequately powered. Table 2Descriptive Statistics for Between-Subjects Comparisons of Treatment GroupsSurvey ItemNeedle Injection (*n* = 17)Jet Injector (*n* = 22)*p*-valuePQ 12.00 (3.00)\*\*2.00 (1.25)\*\*0.488PQ 22.18 (0.95)\*1.50 (0.67)\*0.013PQ 31.88 (0.70)\*1.32 (0.48)\*0.005\*\*\*PQ 41.00 (1.00)\*\*1.00 (0.00)\*\*0.058DQ 15.00 (1.00)\*\*5.00 (0.00)\*\*0.116DQ 22.00 (0.61)\*1.36 (0.49)\*0.001\*\*\*DQ 35.00 (1.00)\*\*5.00 (0.00)\*\*0.006\*\*\*Note: \* *M* (SD), \*\* Median (IQR), \*\*\* *p* \< 0.007

Results {#Sec4}
=======

Thirty-nine patients were enrolled, 17 randomized to the lidocaine injection with needle and 22 to the lidocaine jet injector. Means [+]{.ul} SD and medians with interquartile ranges, in addition to *p*-values can be found in Table [2](#Tab2){ref-type="table"}. Patients seemed to have the same level of concern prior to the procedure, with no statistical or numerical difference in patient question (PQ) 1. A Significant difference was found between the treatment groups for PQ 3, suggesting patients in the jet injector group were less likely to experience pain with the numbing procedure. Although no significant difference was seen between groups for PQ 2 or 4, a potential Type II error was detected. Providers felt that each method of lidocaine delivery was equally convenient (doctor question (DQ) 1). They also perceived the patients in the jet injector group experienced less pain with the administration of anesthesia compared to the needle group (DQ2). Additionally, a significant difference was found between groups for adequacy of anesthesia for the procedure with the jet injector group more consistently being rated as no pain (DQ3).

Discussion {#Sec5}
==========

No prior study has compared local anesthesia delivered with needle versus jet injector for pain with injection, anxiety with the anesthesia method, or efficacy of anesthetic, specifically in regards to insertion or removal of Nexplanon®. In this study, patients had significantly less pain when the local anesthetic was delivered via jet injector. Both traditional needle and jet injector delivery methods produced the desired effect of adequate anesthesia with no significant difference. Additionally, providers did not perceive a difference in ease of use for either method. One limitation of this study is that neither the doctors nor the patients were blinded to the anesthesia method, which could lead to a confirmation bias. Additionally, patients enrolled had already made the decision to utilize Nexplanon® as their choice of contraception, which may have made them less concerned about the anesthesia method or the insertion procedure itself. Future studies are needed and could seek to compare responses to existing validated instruments for pain and situational anxiety. The jet injector device incurs an initial cost (\$662.00 in our experience) and early training in use, with minimal ongoing cost, namely expenses in sterilization of the device after use.

Conclusions {#Sec6}
===========

While Nexplanon® is highly efficacious, easily accessible, and immediate acting \[[@CR5]\], future studies ascertaining whether a patient's fear of needles may cause them to reject this reliable means of contraception would be helpful. Offering an alternative, less painful method of anesthesia has the potential to increase acceptance of point-of-care insertion of this highly effective contraceptive device.
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